Jemeen Sreedharan

Denmark Hill
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Inhibiting glycogen synthase kinase 3 suppresses TDP-43-mediated neurotoxicity in a caspase-dependent manner.

Inhibiting glycogen synthase kinase 3 suppresses TDP-43-mediated neurotoxicity in a caspase-dependent manner.

Journal: Research square

Published: June 12, 2025

Noninvasive quantification of fasciculations to track tofersen therapy in superoxide dismutase 1 amyotrophic lateral sclerosis.

Noninvasive quantification of fasciculations to track tofersen therapy in superoxide dismutase 1 amyotrophic lateral sclerosis.

Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

Published: May 09, 2025

Inhibiting Glycogen Synthase Kinase 3 Suppresses TDP-43-Mediated Neurotoxicity in a Caspase-Dependent Manner.

Inhibiting Glycogen Synthase Kinase 3 Suppresses TDP-43-Mediated Neurotoxicity in a Caspase-Dependent Manner.

Journal: Molecular neurobiology

Published: April 25, 2025

Nose-to-Brain Delivery of Acyl-Ghrelin Peptide Gold Nanoconjugates for Treatment of Neurodegenerative Diseases.

Nose-to-Brain Delivery of Acyl-Ghrelin Peptide Gold Nanoconjugates for Treatment of Neurodegenerative Diseases.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: April 12, 2025

Quantitative Profiling of Nanoscopic Protein Aggregates Reveals Specific Fingerprint of TDP-43-Positive Assemblies in Motor Neuron Disease.

Quantitative Profiling of Nanoscopic Protein Aggregates Reveals Specific Fingerprint of TDP-43-Positive Assemblies in Motor Neuron Disease.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 26, 2025

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Journal: Lancet (London, England)

Published: October 25, 2024

Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy.

Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy.

Journal: The Lancet. Neurology

Published: October 15, 2024

Reduction of RAD23A extends lifespan and mitigates pathology in TDP-43 mice.

Reduction of RAD23A extends lifespan and mitigates pathology in TDP-43 mice.

Journal: bioRxiv : the preprint server for biology

Published: September 24, 2024

Reduction of RAD23A extends lifespan and mitigates pathology in a mouse model of TDP-43 proteinopathy.

Reduction of RAD23A extends lifespan and mitigates pathology in a mouse model of TDP-43 proteinopathy.

Journal: Nature communications

Published: September 05, 2024

Alterations to metabolic hormones in amyotrophic lateral sclerosis and frontotemporal dementia postmortem human tissue.

Alterations to metabolic hormones in amyotrophic lateral sclerosis and frontotemporal dementia postmortem human tissue.

Journal: Journal of neuropathology and experimental neurology

Published: June 25, 2024

Author Correction: Female sex mitigates motor and behavioural phenotypes in TDP-43Q331K knock-in mice.

Author Correction: Female sex mitigates motor and behavioural phenotypes in TDP-43Q331K knock-in mice.

Journal: Scientific reports

Published: May 21, 2021

MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia.

MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia.

Journal: Brain communications

Published: February 23, 2021

Showing 1-12 of 32

Last Updated: 09/26/2026